Skip to content
中文产业新闻精选评分71Chinese source

伏美替尼FURVENT三期试验未达PFS主要终点 公司股价暴跌60%

伏美替尼三期临床失败

Original articleChinese edition

No English body on site. Use the original article link above, or open the Chinese edition for the editorial note.